{"id":11224,"date":"2020-08-05T00:00:00","date_gmt":"2020-08-05T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\/"},"modified":"2025-08-19T08:28:19","modified_gmt":"2025-08-19T13:28:19","slug":"janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2020\/08\/05\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\/","title":{"rendered":"JANSSEN ANNONCE L\u2019APPROBATION PAR SANT\u00c9 CANADA DE DARZALEX\u00ae* SC, UNE NOUVELLE FORMULATION SOUS-CUTAN\u00c9E POUR LE TRAITEMENT DES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE"},"content":{"rendered":"<p>Janssen de Johnson &amp; Johnson a annonc\u00e9 aujourd\u2019hui que Sant\u00e9 Canada a approuv\u00e9 DARZALEX\u00ae SC (daratumumab), une nouvelle formulation sous-cutan\u00e9e de daratumumab.1 DARZALEX\u00ae SC est approuv\u00e9 dans quatre sch\u00e9mas th\u00e9rapeutiques pour cinq indications chez les patients atteints d\u2019un my\u00e9lome multiple, plus particuli\u00e8rement chez les patients nouvellement diagnostiqu\u00e9s, les patients non admissibles \u00e0 une greffe, ainsi que les patients atteints d\u2019un my\u00e9lome r\u00e9cidivant ou r\u00e9fractaire. DARZALEX\u00ae SC est une formulation \u00e0 dose fixe qui peut \u00eatre administr\u00e9e en trois \u00e0 cinq minutes environ, soit beaucoup moins de temps que DARZALEX\u00ae par voie intraveineuse (IV), qui est administr\u00e9 en quelques heures. DARZALEX\u00ae SC est le seul anticorps sous-cutan\u00e9 dirig\u00e9 contre CD38 approuv\u00e9 dans le traitement d\u2019un my\u00e9lome multiple. Cliquez <a href=\"https:\/\/www.newswire.ca\/news-releases\/janssen-announces-health-canada-approval-of-darzalex-r-sc-a-new-subcutaneous-formulation-for-the-treatment-of-patients-with-multiple-myeloma-896235836.html\" target=\"_blank\" rel=\"noopener\"><strong>ici<\/strong><\/a> pour en savoir plus.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Janssen de Johnson &amp; Johnson a annonc\u00e9 aujourd\u2019hui que Sant\u00e9 Canada a approuv\u00e9 DARZALEX\u00ae SC (daratumumab), une nouvelle formulation sous-cutan\u00e9e de daratumumab.1 DARZALEX\u00ae SC est approuv\u00e9 dans quatre sch\u00e9mas th\u00e9rapeutiques pour cinq indications chez les patients atteints d\u2019un my\u00e9lome multiple, plus particuli\u00e8rement chez les patients nouvellement diagnostiqu\u00e9s, les patients non admissibles \u00e0 une greffe, ainsi [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11224","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.0.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Janssen de Johnson &amp; Johnson a annonc\u00e9 aujourd\u2019hui que Sant\u00e9 Canada a approuv\u00e9 DARZALEX\u00ae SC (daratumumab), une nouvelle formulation sous-cutan\u00e9e de daratumumab.1 DARZALEX\u00ae SC est approuv\u00e9 dans quatre sch\u00e9mas th\u00e9rapeutiques pour cinq indications chez les patients atteints d\u2019un my\u00e9lome multiple, plus particuli\u00e8rement chez les patients nouvellement diagnostiqu\u00e9s, les patients non admissibles \u00e0 une greffe, ainsi\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"lemieuxbedard\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/myeloma.ca\/fr\/2020\/08\/05\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.0.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"My\u00e9lome Canada |\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"JANSSEN ANNONCE L\u2019APPROBATION PAR SANT\u00c9 CANADA DE DARZALEX\u00ae* SC, UNE NOUVELLE FORMULATION SOUS-CUTAN\u00c9E POUR LE TRAITEMENT DES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE | My\u00e9lome Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"Janssen de Johnson &amp; Johnson a annonc\u00e9 aujourd\u2019hui que Sant\u00e9 Canada a approuv\u00e9 DARZALEX\u00ae SC (daratumumab), une nouvelle formulation sous-cutan\u00e9e de daratumumab.1 DARZALEX\u00ae SC est approuv\u00e9 dans quatre sch\u00e9mas th\u00e9rapeutiques pour cinq indications chez les patients atteints d\u2019un my\u00e9lome multiple, plus particuli\u00e8rement chez les patients nouvellement diagnostiqu\u00e9s, les patients non admissibles \u00e0 une greffe, ainsi\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/myeloma.ca\/fr\/2020\/08\/05\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2020-08-05T05:00:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-08-19T13:28:19+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"JANSSEN ANNONCE L\u2019APPROBATION PAR SANT\u00c9 CANADA DE DARZALEX\u00ae* SC, UNE NOUVELLE FORMULATION SOUS-CUTAN\u00c9E POUR LE TRAITEMENT DES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE | My\u00e9lome Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Janssen de Johnson &amp; Johnson a annonc\u00e9 aujourd\u2019hui que Sant\u00e9 Canada a approuv\u00e9 DARZALEX\u00ae SC (daratumumab), une nouvelle formulation sous-cutan\u00e9e de daratumumab.1 DARZALEX\u00ae SC est approuv\u00e9 dans quatre sch\u00e9mas th\u00e9rapeutiques pour cinq indications chez les patients atteints d\u2019un my\u00e9lome multiple, plus particuli\u00e8rement chez les patients nouvellement diagnostiqu\u00e9s, les patients non admissibles \u00e0 une greffe, ainsi\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/08\\\/05\\\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\\\/#blogposting\",\"name\":\"JANSSEN ANNONCE L\\u2019APPROBATION PAR SANT\\u00c9 CANADA DE DARZALEX\\u00ae* SC, UNE NOUVELLE FORMULATION SOUS-CUTAN\\u00c9E POUR LE TRAITEMENT DES PATIENTS ATTEINTS D\\u2019UN MY\\u00c9LOME MULTIPLE | My\\u00e9lome Canada\",\"headline\":\"JANSSEN ANNONCE L\\u2019APPROBATION PAR SANT\\u00c9 CANADA DE DARZALEX\\u00ae* SC, UNE NOUVELLE FORMULATION SOUS-CUTAN\\u00c9E POUR LE TRAITEMENT DES PATIENTS ATTEINTS D\\u2019UN MY\\u00c9LOME MULTIPLE\",\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#articleImage\"},\"datePublished\":\"2020-08-05T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:19-05:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/08\\\/05\\\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/08\\\/05\\\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\\\/#webpage\"},\"articleSection\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement, News &amp; Events, Nouvelles de My\\u00e9lome Canada, What's new at Myeloma Canada, Facultatif, Optional\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/08\\\/05\\\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"name\":\"News &amp; Events\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"position\":2,\"name\":\"News &amp; Events\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"name\":\"What's new at Myeloma Canada\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"name\":\"Accueil\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"position\":3,\"name\":\"What's new at Myeloma Canada\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/08\\\/05\\\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\\\/#listItem\",\"name\":\"JANSSEN ANNONCE L\\u2019APPROBATION PAR SANT\\u00c9 CANADA DE DARZALEX\\u00ae* SC, UNE NOUVELLE FORMULATION SOUS-CUTAN\\u00c9E POUR LE TRAITEMENT DES PATIENTS ATTEINTS D\\u2019UN MY\\u00c9LOME MULTIPLE\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"name\":\"News &amp; Events\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/08\\\/05\\\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\\\/#listItem\",\"position\":4,\"name\":\"JANSSEN ANNONCE L\\u2019APPROBATION PAR SANT\\u00c9 CANADA DE DARZALEX\\u00ae* SC, UNE NOUVELLE FORMULATION SOUS-CUTAN\\u00c9E POUR LE TRAITEMENT DES PATIENTS ATTEINTS D\\u2019UN MY\\u00c9LOME MULTIPLE\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"name\":\"What's new at Myeloma Canada\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\",\"name\":\"Myeloma Canada\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"telephone\":\"+18887985771\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/08\\\/05\\\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/08\\\/05\\\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/\",\"name\":\"lemieuxbedard\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/08\\\/05\\\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"lemieuxbedard\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/08\\\/05\\\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\\\/#webpage\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/08\\\/05\\\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\\\/\",\"name\":\"JANSSEN ANNONCE L\\u2019APPROBATION PAR SANT\\u00c9 CANADA DE DARZALEX\\u00ae* SC, UNE NOUVELLE FORMULATION SOUS-CUTAN\\u00c9E POUR LE TRAITEMENT DES PATIENTS ATTEINTS D\\u2019UN MY\\u00c9LOME MULTIPLE | My\\u00e9lome Canada\",\"description\":\"Janssen de Johnson & Johnson a annonc\\u00e9 aujourd\\u2019hui que Sant\\u00e9 Canada a approuv\\u00e9 DARZALEX\\u00ae SC (daratumumab), une nouvelle formulation sous-cutan\\u00e9e de daratumumab.1 DARZALEX\\u00ae SC est approuv\\u00e9 dans quatre sch\\u00e9mas th\\u00e9rapeutiques pour cinq indications chez les patients atteints d\\u2019un my\\u00e9lome multiple, plus particuli\\u00e8rement chez les patients nouvellement diagnostiqu\\u00e9s, les patients non admissibles \\u00e0 une greffe, ainsi\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/08\\\/05\\\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"datePublished\":\"2020-08-05T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:19-05:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"name\":\"Myeloma Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"JANSSEN ANNONCE L\u2019APPROBATION PAR SANT\u00c9 CANADA DE DARZALEX\u00ae* SC, UNE NOUVELLE FORMULATION SOUS-CUTAN\u00c9E POUR LE TRAITEMENT DES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE | My\u00e9lome Canada","description":"Janssen de Johnson & Johnson a annonc\u00e9 aujourd\u2019hui que Sant\u00e9 Canada a approuv\u00e9 DARZALEX\u00ae SC (daratumumab), une nouvelle formulation sous-cutan\u00e9e de daratumumab.1 DARZALEX\u00ae SC est approuv\u00e9 dans quatre sch\u00e9mas th\u00e9rapeutiques pour cinq indications chez les patients atteints d\u2019un my\u00e9lome multiple, plus particuli\u00e8rement chez les patients nouvellement diagnostiqu\u00e9s, les patients non admissibles \u00e0 une greffe, ainsi","canonical_url":"https:\/\/myeloma.ca\/fr\/2020\/08\/05\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/myeloma.ca\/fr\/2020\/08\/05\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\/#blogposting","name":"JANSSEN ANNONCE L\u2019APPROBATION PAR SANT\u00c9 CANADA DE DARZALEX\u00ae* SC, UNE NOUVELLE FORMULATION SOUS-CUTAN\u00c9E POUR LE TRAITEMENT DES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE | My\u00e9lome Canada","headline":"JANSSEN ANNONCE L\u2019APPROBATION PAR SANT\u00c9 CANADA DE DARZALEX\u00ae* SC, UNE NOUVELLE FORMULATION SOUS-CUTAN\u00c9E POUR LE TRAITEMENT DES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE","author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/#articleImage"},"datePublished":"2020-08-05T00:00:00-05:00","dateModified":"2025-08-19T08:28:19-05:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/myeloma.ca\/fr\/2020\/08\/05\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\/#webpage"},"isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/2020\/08\/05\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\/#webpage"},"articleSection":"Actualit\u00e9s et \u00e9v\u00e9nement, News &amp; Events, Nouvelles de My\u00e9lome Canada, What's new at Myeloma Canada, Facultatif, Optional"},{"@type":"BreadcrumbList","@id":"https:\/\/myeloma.ca\/fr\/2020\/08\/05\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","position":1,"name":"Accueil","item":"https:\/\/myeloma.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","name":"News &amp; Events"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","position":2,"name":"News &amp; Events","item":"https:\/\/myeloma.ca\/category\/news-events\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","name":"What's new at Myeloma Canada"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","name":"Accueil"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","position":3,"name":"What's new at Myeloma Canada","item":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2020\/08\/05\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\/#listItem","name":"JANSSEN ANNONCE L\u2019APPROBATION PAR SANT\u00c9 CANADA DE DARZALEX\u00ae* SC, UNE NOUVELLE FORMULATION SOUS-CUTAN\u00c9E POUR LE TRAITEMENT DES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","name":"News &amp; Events"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2020\/08\/05\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\/#listItem","position":4,"name":"JANSSEN ANNONCE L\u2019APPROBATION PAR SANT\u00c9 CANADA DE DARZALEX\u00ae* SC, UNE NOUVELLE FORMULATION SOUS-CUTAN\u00c9E POUR LE TRAITEMENT DES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE","previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","name":"What's new at Myeloma Canada"}}]},{"@type":"Organization","@id":"https:\/\/myeloma.ca\/fr\/#organization","name":"Myeloma Canada","url":"https:\/\/myeloma.ca\/fr\/","telephone":"+18887985771","logo":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/2020\/08\/05\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\/#organizationLogo"},"image":{"@id":"https:\/\/myeloma.ca\/fr\/2020\/08\/05\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author","url":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/","name":"lemieuxbedard","image":{"@type":"ImageObject","@id":"https:\/\/myeloma.ca\/fr\/2020\/08\/05\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g","width":96,"height":96,"caption":"lemieuxbedard"}},{"@type":"WebPage","@id":"https:\/\/myeloma.ca\/fr\/2020\/08\/05\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\/#webpage","url":"https:\/\/myeloma.ca\/fr\/2020\/08\/05\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\/","name":"JANSSEN ANNONCE L\u2019APPROBATION PAR SANT\u00c9 CANADA DE DARZALEX\u00ae* SC, UNE NOUVELLE FORMULATION SOUS-CUTAN\u00c9E POUR LE TRAITEMENT DES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE | My\u00e9lome Canada","description":"Janssen de Johnson & Johnson a annonc\u00e9 aujourd\u2019hui que Sant\u00e9 Canada a approuv\u00e9 DARZALEX\u00ae SC (daratumumab), une nouvelle formulation sous-cutan\u00e9e de daratumumab.1 DARZALEX\u00ae SC est approuv\u00e9 dans quatre sch\u00e9mas th\u00e9rapeutiques pour cinq indications chez les patients atteints d\u2019un my\u00e9lome multiple, plus particuli\u00e8rement chez les patients nouvellement diagnostiqu\u00e9s, les patients non admissibles \u00e0 une greffe, ainsi","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/myeloma.ca\/fr\/2020\/08\/05\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\/#breadcrumblist"},"author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"creator":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"datePublished":"2020-08-05T00:00:00-05:00","dateModified":"2025-08-19T08:28:19-05:00"},{"@type":"WebSite","@id":"https:\/\/myeloma.ca\/fr\/#website","url":"https:\/\/myeloma.ca\/fr\/","name":"Myeloma Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"My\u00e9lome Canada |","og:type":"article","og:title":"JANSSEN ANNONCE L\u2019APPROBATION PAR SANT\u00c9 CANADA DE DARZALEX\u00ae* SC, UNE NOUVELLE FORMULATION SOUS-CUTAN\u00c9E POUR LE TRAITEMENT DES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE | My\u00e9lome Canada","og:description":"Janssen de Johnson &amp; Johnson a annonc\u00e9 aujourd\u2019hui que Sant\u00e9 Canada a approuv\u00e9 DARZALEX\u00ae SC (daratumumab), une nouvelle formulation sous-cutan\u00e9e de daratumumab.1 DARZALEX\u00ae SC est approuv\u00e9 dans quatre sch\u00e9mas th\u00e9rapeutiques pour cinq indications chez les patients atteints d\u2019un my\u00e9lome multiple, plus particuli\u00e8rement chez les patients nouvellement diagnostiqu\u00e9s, les patients non admissibles \u00e0 une greffe, ainsi","og:url":"https:\/\/myeloma.ca\/fr\/2020\/08\/05\/janssen-annonce-lapprobation-par-sante-canada-de-darzalex-sc-une-nouvelle-formulation-sous-cutanee-pour-le-traitement-des-patients-atteints-dun-myelome-multiple\/","article:published_time":"2020-08-05T05:00:00+00:00","article:modified_time":"2025-08-19T13:28:19+00:00","twitter:card":"summary_large_image","twitter:title":"JANSSEN ANNONCE L\u2019APPROBATION PAR SANT\u00c9 CANADA DE DARZALEX\u00ae* SC, UNE NOUVELLE FORMULATION SOUS-CUTAN\u00c9E POUR LE TRAITEMENT DES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE | My\u00e9lome Canada","twitter:description":"Janssen de Johnson &amp; Johnson a annonc\u00e9 aujourd\u2019hui que Sant\u00e9 Canada a approuv\u00e9 DARZALEX\u00ae SC (daratumumab), une nouvelle formulation sous-cutan\u00e9e de daratumumab.1 DARZALEX\u00ae SC est approuv\u00e9 dans quatre sch\u00e9mas th\u00e9rapeutiques pour cinq indications chez les patients atteints d\u2019un my\u00e9lome multiple, plus particuli\u00e8rement chez les patients nouvellement diagnostiqu\u00e9s, les patients non admissibles \u00e0 une greffe, ainsi"},"aioseo_meta_data":{"post_id":"11224","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2023-09-18 17:02:42","updated":"2026-04-30 07:24:29","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11224","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11224"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11224\/revisions"}],"predecessor-version":[{"id":31314,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11224\/revisions\/31314"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11224"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11224"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11224"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}